1 / 36

Adrenal Carcinoma

Adrenal Carcinoma. Dr. D.W. Daugherty. Epidemiology. Estimated incidence of 0.5-2 per 10 6 patients per year Peaks of age distribution at age <5 and in the 4 th and 5 th decades Scattered reports of gene associations, but rarity of lesion limits studies – no clear associations.

max
Télécharger la présentation

Adrenal Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Adrenal Carcinoma Dr. D.W. Daugherty

  2. Epidemiology • Estimated incidence of 0.5-2 per 106 patients per year • Peaks of age distribution at age <5 and in the 4th and 5th decades • Scattered reports of gene associations, but rarity of lesion limits studies – no clear associations

  3. Functioning Lesions • 60-65% of adrenocortical carcinomas are functioning lesions • Cushings • Virilization • Feminization • Hyperaldosteronism

  4. Diagnostics • Hormonal studies can be a first diagnostic test which confirms ectopic steroid hormone secretion, leading to an imaging and tissue diagnosis. • They also can be a “tumor marker” which can be useful for monitoring response to therapy and suspicion of recurrence.

  5. Hypercortisolism • 24 hour urinary cortisol exrection • More than 90% of Cushinoid patients have free cortisol levels greater than 200mcg/ 24 hours. 97% of normals have levels less than 100mcg/ 24 hours ACTH measured with serum cortisol will demonstrate ACTH independent nature of hypercortisolism.

  6. Other Steroids • Other steroids are elevated: • androstenediol and adrosetenedione • DHEA and DHEA-S • 11- deoxycortisol • urinary 17- ketosteroids • aldosterone • Many intermediate enzymes are defective or dysregulated, leading to inefficient steroid production and precursor accumulation

  7. Potential Functional Assays • Serum Testosterone • Serum DHEA and DHEA-S • 24 hour urinary ketosteroids • Plasma estradiol and/ or estrone • Plasma aldosterone/ renin • Urinary catecholamines/ metanephrines in all patients

  8. Imaging • CT detects 98% of adrenal carcinomas • MRI scanning can also provide vascular invasion/ tumor thrombosis information. • Many incidental findings? • Malignant lesions tend to be > 5cm, have irregular shapes/ blurred margins, and be heterogeneously enhancing.

  9. Staging • Hormonal studies directed at symptoms • 24h urine studies to r/o pheochromocytoma • CT scanning to determine extent and resectability of lesion • MRI may clarify vascular invasion; right sided lesions have a propensity to form venous tumor emboli

  10. Staging • Stage I — Disease confined to the adrenal gland and <5 cm in diameter (approx 20%) • Stage II — Disease confined to the adrenal gland and >5 cm in diameter (approx 20%) • Stage III — Local invasion that does not involve adjacent organs or regional lymph nodes (approx 20%) • Stage IV — Distant metastases or invasion into adjacent organs plus regional lymph nodes (approx 40%)

  11. Surgery • Complete surgical resection is the primary treatment modality

  12. Post- Resection Survival Complete resection is the strongest predictor of survival

  13. Incomplete resection is associated with a uniformly poor prognosis, with less than a 1 year median survival

  14. Resectability • Unresectable tumors include those that invade the celiac plexus/ vascular structures/ SMA/ aorta

  15. Prognostic factors • In a case review of 46 patients at MSKCC, 3 histologic factors correlated with survival: • Tumor > 12cm • 6 or more mitotic figures/ 10hpf • presence of histologic evidence of intra-tumoral hemorrhage • 5 year survivals: • 0 factors: 83% • 1 factor: 42% • 2 factors: 33%

  16. Treatment • Adrenalectomy • Prednisone for steroid replacement • Patients with glucocorticoid producing tumors postoperatively will need replacement due to suppression of the remaining adrenal

  17. Radiation Approach • There are emerging case reports demonstrating improved outcomes when palliative XRT used for localized lesions

  18. Chemotherapeutic Approach • Emerging case reports, retrospective treatment data, and reviews are beginning to support this approach.

  19. Mitotane • 1,1- dichloro-2-(o-chlorophenyl) ethane (o,p-DDD). • Chemical relative to DDT • Found to have adrenolytic activity in dogs in vivo (selectively destroyed the zonae reticularis and fasciculata)

  20. Mitotane • inhibits the mitochondrialconversion of cholesterol to pregnenolone and the conversionof 11-deoxycortisol to cortisol (11B- hydroxylation). It produces selective adrenocorticalnecrosis in both the adrenal tumor and metastases

  21. Mitotane • Side effects are major and frequent, including: • CNS disturbance (vertigo, somnolence, ataxia) • Liver Toxicity • Renal Toxicity • Nausea, Vomiting • Diarrhea • Rash

  22. Selected Mitotane Studies

  23. Other symptom- palliative Options • Metyrapone (11B hydroxylase inhibitor) • Ketoconazole • Aminoglutehamide

  24. Cytotoxics • Various systemic cytotoxics have been used for advanced disease, usually for those failing mitotane. • Most studied have been Etoposide, cisplatin, and adriamycin. • Paclitaxel and Temozolamide have recently demonstrated antitumor activity in vitro

  25. Combos • Original studies utilized Cisplatin and Doxorubicin with Cyclophosphamide or 5-FU. RR was 20% • Cisplatin/ Etoposide reported to have an 11% response rate

  26. Overview of Chemo Trials

  27. MDR issues • P-Glycoprotein (Pgp) is expressed widely in normal adrenal and adrenocortical carcinoma cells • In vitro, mitotane inhibits the Pgp efflux pump at concentrations achieved with mitotane therapy

  28. EDP-M • Italian study • 28 patients enrolled • Etoposide (100mg/ m2) d5-7; Doxorubicin (20mg/ m2) d1,8; Cisplatin (40mg/ m2) d1,9 every 4 weeks • Concomitant mitotane up to 4g/ day

  29. EDP-M • CR in 2 patients • PR in 13 patients • Overall response of 54% • Stable disease in 8, progessive in 5 • Median TTP of 24 months in responders

  30. Recurrences • Recurrences that are amenable to re- operation may be resected for long term survival • 5 year survivals compare from 57% in those amenable to resection to 0% for those who are not

  31. Recurrences • Italian registry: 140 resections • Recurrences in 52 (37%) • Locally in 13 • Distant in 25 • Local + Distant in 14 • 20 patients underwent re- resection • 5 yr survival of 50% in those resected • 5 yr survival of 8% in those not resected

  32. Recurrences • MSKCC: 47 patients with recurrent/ metastatic disease • Patients who had a complete second resection had a median survival of 74 months (5-year survival, 57%), whereas those with incomplete second resection had a median survival of 16 months (5-year survival, 0%).

  33. Summary • Adrenocortical carcinoma is a rare disease that often presents late • Primary curative therapy is surgical • No role for adjuvant chemotherapy has been definitively demonstrated to date • Palliative therapy with mitotane may be useful; its palliative effect may be entirely due to adrenolytic effect

  34. Summary • Re-operation appears to be the only long term curative option in recurrent cases • Cytotoxic chemotherapy in the advanced/ metastatic setting has not been definitively demonstrated to be useful in controlled trials • EDP-M may be useful in metastatic settings; evaluation is ongoing

  35. Thank You

More Related